Paccal Vet is being evaluated in an open-label, exploratory pilot study in dogs with various stages of splenic hemangiosarcoma (HSA) after splenectomy. The study aims to include up to 23 patients and consists of four treatment cycles with Paccal Vet (paclitaxel micellar). It is being conducted at eight clinical centers in Washington, Oregon, Colorado, and California. An interim analysis of the first cohort’s results is expected in summer 2025. If results are positive, a pivotal study will follow to confirm the pilot study’s findings and gather additional clinical evidence on safety and efficacy in the indication.
Read more about the study here and apply to participate in the study here.